van Hoeven Karen H, Dale Connie, Foster Phil, Body Barbara
The Binding Site, Inc., 5889 Oberlin Dr., Ste. 101, San Diego, CA 92121, USA.
Clin Vaccine Immunol. 2008 Dec;15(12):1751-4. doi: 10.1128/CVI.00254-08. Epub 2008 Oct 8.
Accurate determination of the concentrations of immunoglobulin G (IgG) antibody to tetanus toxoid is important in order to evaluate the immunogenicity of tetanus toxoid vaccines, determine immune competence in individual patients, and measure the prevalence of immunity in populations. The performance of three commercially available enzyme-linked immunosorbent assays (ELISAs) for IgG antibodies to tetanus toxoid were evaluated. Serially diluted NIBSC 76/589 and TE-3 human tetanus IgG immunoglobulin international reference standards were analyzed in quadruplicate using ELISAs manufactured by The Binding Site, Inc. (VaccZyme); Scimedx; and Euroimmun. In addition, IgG antibodies to tetanus toxoid were measured in 83 deidentified serum specimens using each manufacturer's ELISA. Each ELISA provided linear results when evaluated with the reference preparations. The Binding Site ELISA provided results that closely corresponded to the reference preparations (y=1.09x-0.08), whereas the Scimedx ELISA gave results that were consistently lower (y=0.21x-0.07) and the Euroimmun ELISA gave results that were consistently higher (y=1.5x+0.30) than the reference preparation concentrations. Using the recommended cutoff for each ELISA (<0.10 IU/ml), the overall agreement of all of the ELISA methods was 78%. Three of eighty-three (3.6%) human serum samples demonstrated inadequate immunity with all three assays. The Binding Site ELISA yielded nonprotective antibody concentrations in only these 3 samples, whereas 19 samples (22.9%) according to the Scimedx ELISA and 6 samples (7.2%) according to the Euroimmun ELISA demonstrated nonprotective concentrations. The performance characteristics of ELISAs for tetanus immunoglobulin titers were manufacturer dependent, and the differences translated into important disparities in reported results.
准确测定破伤风类毒素免疫球蛋白G(IgG)抗体的浓度对于评估破伤风类毒素疫苗的免疫原性、确定个体患者的免疫能力以及测量人群中的免疫流行率非常重要。对三种市售的破伤风类毒素IgG抗体酶联免疫吸附测定(ELISA)的性能进行了评估。使用The Binding Site公司(VaccZyme)、Scimedx和Euroimmun生产的ELISA对系列稀释的NIBSC 76/589和TE-3人破伤风IgG免疫球蛋白国际参考标准品进行了一式四份分析。此外,使用每个制造商的ELISA对83份身份不明的血清标本中的破伤风类毒素IgG抗体进行了测量。用参考制剂评估时,每种ELISA均提供线性结果。The Binding Site ELISA提供的结果与参考制剂密切对应(y = 1.09x - 0.08),而Scimedx ELISA给出的结果始终较低(y = 0.21x - 0.07),Euroimmun ELISA给出的结果始终高于参考制剂浓度(y = 1.5x + 0.30)。使用每种ELISA推荐的临界值(<0.10 IU/ml),所有ELISA方法的总体一致性为78%。83份人血清样本中有3份(3.6%)在所有三种检测中均显示免疫不足。The Binding Site ELISA仅在这3个样本中产生了非保护性抗体浓度,而根据Scimedx ELISA有19个样本(22.9%),根据Euroimmun ELISA有6个样本(7.2%)显示出非保护性浓度。破伤风免疫球蛋白滴度ELISA的性能特征取决于制造商,这些差异导致报告结果出现重要差异。